Johns Hopkins ABX Guide
Micafungin
INDICATIONS
FDA
FDA
- Prophylaxis of Candida infections in hematopoietic stem cell transplant pts (HSCT)
- Treatment of esophageal candidiasis
- IDSA Guidelines recommend echinocandins for azole-refractory or resistant disease
- Treatment of patients with candidemia, acute disseminated candidiasis, candida peritonitis and abscesses
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Invasive aspergillosis (known data limited to open-label studies[10]).
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: October 18, 2022
Citation
Dzintars, Kathryn, and Paul G Auwaerter. "Micafungin." Johns Hopkins ABX Guide, The Johns Hopkins University, 2022. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540348/all/Micafungin.
Dzintars K, Auwaerter PG. Micafungin. Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540348/all/Micafungin. Accessed December 18, 2024.
Dzintars, K., & Auwaerter, P. G. (2022). Micafungin. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540348/all/Micafungin
Dzintars K, Auwaerter PG. Micafungin [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. [cited 2024 December 18]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540348/all/Micafungin.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Micafungin
ID - 540348
A1 - Dzintars,Kathryn,Pharm.D., BCPS
AU - Auwaerter,Paul,M.D.
Y1 - 2022/10/18/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540348/all/Micafungin
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
